

The STATus Report

Seabreeze STAT COPD (CBP-201-207) Update

Volume 2 – Issue 6

June 2026 Topics:

- ❖ Monthly Message & Enrollment Update
- ❖ Study Reminders
- ❖ Questions & Answers

Monthly Message

ANNOUNCEMENT

- ❖ Pre-screening logs for Channel 1 will not be accepted after **01 June 2026**
- ❖ Screening at Visit 1a for Channel 1 ends on **08 June 2026**
- ❖ Channel 2 screening will continue until 160 participants are randomized

American Thoracic Society - ATS

The Connect team attended the ATS 2026 conference in Orlando, Florida. Research in COPD continues to focus on examining various clinical indicators to optimize treatment.

Presentations on pooled analysis from large phase 3 trials support monitoring blood eosinophil counts to guide treatment for COPD and asthma type 2 exacerbations.




May Highlights

Congratulations to the following sites who screened their first participants last month:

1134 Mulamula
1135 Baalachandran
1609 Wehbe

Enrollment Update

Goal = 160 Patients



Top Enrollers - May (as of 28 May 2026)

❖ 1303	Mojsilović	3 participants
❖ 1304	Djuric	2 participants
❖ 1309	Jovanović	2 participants
❖ 1402	Peikrishvili	2 participants
❖ 1613	Larivey	2 participants

In Focus: Clinical Brief

Question & Answers

Q: If the local lab obtained at Visit 1b provides only serum urea, can sites calculate BUN values for eligibility?

A: Yes, however this is a protocol deviation since BUN is required. The calculated BUN should be entered in EDC along with the calculated normal ranges.


Q: What does “approximately 12 months prior to Screening” mean for Inclusion #5?

A: Starting with Protocol Amendment 3, “approximately 12 months” includes a small allowance beyond 12 months—about 3–4 weeks. This means patients may still qualify if their COPD exacerbation (requiring systemic corticosteroids) occurred slightly more than 12 months before Screening, within this extended window.

Q: If a channel 1 participant was consented prior to end of day June 8, can sites continue screening activities for eligibility determination?

A: Yes. While no new screening can be initiated after June 8, participants who were already in screening before this date may continue with assessments required to determine eligibility at Visit 1a. Participants already enrolled in Channel 1 can continue awaiting exacerbation until randomization has closed.

Randomizations per Region (as of 28 May 2026)



Study Reminders

- ❖ Continue to enter study data within 5 days of a visit and answer queries promptly as part of data cleaning.
- ❖ Treatment Failure Log Forms should be completed on a rolling basis and at EOT.
- ❖ Refer to updated CCGs while completing eCRFs.

Seabreeze STAT COPD Resources

Check out seabreezestatcopd.com for:

- ❖ Operational manuals
 - Lab, Pharmacy, CRF Completion Guidelines, Quick Access Guide
- ❖ SIV slides, Questions & Answers from all newsletters



ZEPHYRx Data Change Requests

If a change to ZEPHYRx data is required (for example, wrong patient selected), please use the study specific *Data Change Request Form* to modify study information.

This form has been uploaded to the Seabreeze study website. **ZEPHYRx Data Change Request Form**

Complete the form fully, including the subject number and the data you want modified. Send the completed form to support@zephyrx.com. ZEPHYRx will make the changes in the system. Ensure a copy of the Data Change Request Form is filed in your Investigator Site Binder.

ZEPHYRx Data Change Request Form
SEABREEZE COPD (CBP-201-207)
v1.0, May 2025

Please complete the assigned fields and sign and date the document. For any questions please contact support@zephyrx.com

Person Requesting Data Change:

Email:

Contact Tel:

Site Number:

Site Name:

Investigator Name:

Change Requested & Reason: (enter as much detail as possible and be as specific as possible)

Print Name:

Signature:

Date:

Walk Your Way



Connect Biopharma supports the Lung Force Walk

This event was held at the Flower Fields Carlsbad on May 31, 2026. The American Lung Association's LUNG FORCE initiative unites women, men and caregivers across the United States to stand together for lung health.

Support for Patients with Asthma or COPD

Consider joining a national or regional event that provides support for patients with asthma or COPD in the coming months.

- ❖ Perhaps you braved **Larapinta Adventure 2026**- a 4-day trek hosted by **Lung Foundation Australia** in May.
- ❖ Consider a team for **Love Your Lungs Week 2026** hosted by **Asthma + Lung UK** in late June
- ❖ Connect Biopharma participated in the **American Lung Association's Lung Force Walk** in San Diego in May.

WE WANT TO HEAR FROM YOU!!

What would be helpful for your site to read about in future newsletters?
Please email us at Clinical207@connectpharm.com.